Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShort-Term Debt repayments
Ratios

China Pharma Holdings (CPHI) Other Gross PP&E Adjustments (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Other Gross PP&E Adjustments for 15 consecutive years, with $37.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Gross PP&E Adjustments fell 1.54% year-over-year to $37.3 million, compared with a TTM value of $37.3 million through Sep 2025, down 1.54%, and an annual FY2024 reading of $36.9 million, down 1.16% over the prior year.
  • Other Gross PP&E Adjustments was $37.3 million for Q3 2025 at China Pharma Holdings, roughly flat from $37.2 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $37.9 million in Q3 2024 and bottomed at -$25369.0 in Q1 2021.
  • Average Other Gross PP&E Adjustments over 5 years is $19.4 million, with a median of $28.5 million recorded in 2022.
  • The sharpest move saw Other Gross PP&E Adjustments crashed 105.37% in 2021, then surged 6978.34% in 2024.
  • Year by year, Other Gross PP&E Adjustments stood at $488309.0 in 2021, then soared by 5733.46% to $28.5 million in 2022, then surged by 31.21% to $37.4 million in 2023, then dropped by 1.16% to $36.9 million in 2024, then increased by 0.91% to $37.3 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for CPHI at $37.3 million in Q3 2025, $37.2 million in Q2 2025, and $37.1 million in Q1 2025.